News and Treatment Updates

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Against all odds: Unrelated stem cell transplants in coronavirus times

Original Publication Date
Article Source
External Web Content
The COVID-19 crisis has consequences not only for those who have become infected and the doctors and nurses who care for them. The care of other patients is also threatened by the increasing stress that national health systems and societies as a whole are under. Also, cancer has…

Coronavirus 2019: What People With Cancer Need to Know

Original Publication Date
Article Source
External Web Content
Coronavirus 2019: What People With Cancer Need to Know Merry Jennifer Markham, MD, FACP March 25, 2020 · Merry Jennifer Markham, MD, FACP This post is reviewed and updated every day. It was first published on March 3. Merry Jennifer Markham, MD, FACP, is the Interim Chief of the…

Coronavirus: What People with Cancer Should Know

Original Publication Date
Article Source
External Web Content
Coronavirus: What People with Cancer Should Know ON THIS PAGE What is coronavirus, or COVID-19? If I have cancer, am I at higher risk of getting or dying from COVID-19? If I have cancer, how can I protect myself? I receive cancer treatment at a medical facility. What should I do…

Stuck Inside? Come Hang Out With The Mighty Community!

Original Publication Date
Article Source
External Web Content
Join The Mighty’s staff and community for a series of events designed to put the SOCIAL in social distancing. We’ve got writing workshops, fun events for kids, interactive Facebook Lives, and more! Check out the schedule (con't)

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

Original Publication Date
Article Source
External Web Content
Ruben Mesa, MD Newly approved and investigational agents are joining ruxolitinib (Jakafi) for the treatment of myelofibrosis (MF) and may provide options for patients who progress or become intolerant to frontline JAK inhibitors. At the 24th Annual International Congress on…

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.

We Recommend

For Patients and Families